

This combined research product features Retatrutide and Cagrilintide, with a declared total strength of 45mg. Researchers should note that individual component amounts are not specified by the combined strength. It is important to request exact formulation and batch documentation for specific research needs. This product is strictly for laboratory research and not intended for human or animal consumption.
Every Evora batch is third-party tested before release. See the certificate of analysis on our COAs page.
Loading reviews…
Choose the right injection area
Use the abdomen or the upper legs. Divide the area you choose into four sections and move to a new section each week, so the same spot is not used again too soon.
- Abdomen or upper legs
- Switch injection sites weekly
- At least one finger width from the last injection
- At least 5 cm away from the navel
General guidance only. Always follow the instructions supplied with your product.
UK delivery is a flat £10.00 with tracking (international £35.00). Orders placed before 2pm Monday to Friday are dispatched the same day.
International shipping is available to selected countries. See our shipping policy for details.
RETATRUTIDE & CAGRILINTIDE 45mg: product information
This listing is a combined formulation of retatrutide and cagrilintide with a declared total strength of 45mg. The total does not show the amount of each peptide, so request the formulation and batch documentation before ordering if you need the exact split.
Frequently asked questions
How is this different from RETAKLIK 2.0?
Is it a licensed medicine?
Is there a certificate of analysis?
How should it be stored?
How much is delivery?
Related products: RETAKLIK 2.0 (RETATRUTIDE + CAGRILINTIDE) 30+5mg · Reta + Cag bundle · KLIKTIDE (CAGRILINTIDE) 10mg · Retatrutide 40mg Bundle · Lab reports (COAs)


